⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.
Ruxolitinib (JAK Inhibition)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-07-12 — Targeting the JAK-STAT signaling pathway ameliorates chemotherapy-induced skin aging.: cross-connection with senomorphics: Positions ruxolitinib as a JAK-STAT–directed senomorphic for chemotherapy-induced cutaneous senescence/SASP, extending its senomorphic profile beyond hematologic indications. (novelty: 3)
Open questions
Related
Contributing findings
Senomorphic agents: Multi-target strategies to tame the senescence-associated secretory phenotype for healthy ageing.
24-jul-2026
novelty 2
per-area 2
introduces